Skip to main content


Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Fig. 5

AZD1775 enhances olaparib’s antitumor efficacy via HR defect in vivo. AZD1775 (30 mg/kg/d, by gavage) with/without olaparib (25 mg/kg/d, ip) were given to mice bearing MKN45 tumors for 21 days (n = 5 per group). a Tumor volume was measured every 3 days after treatment and xenograft growth curves were shown. Data expressed as Mean ± SD. *P < 0.05 by repeated measures ANOVA analysis. b and c FFPE sections were stained with Ki-67 using IHC and tumor lysates were immunoblotted for indicated proteins. Original magnification, 200×. AZD, AZD1775; Ola, olaparib; Com, Combination

Back to article page